Local Regulatory Partner for EU & US
Facilitating Safe and Effective Pharmaceuticals through Local Regulatory Collaboration
Facilitating Safe and Effective Pharmaceuticals through Local Regulatory Collaboration
In the pharmaceutical sector,local health authorities generally collaborate with pharmaceutical companies to supervise and approve medications and medical equipment for efficacy and safety. This process involves examining clinical trial data, monitoring post-approval safety, and inspecting manufacturing facilities. Several important health agencies include the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the US Food and Drug Administration (FDA). These organisations are essential in maintaining public health because they establish guidelines and implement rules pertaining to the creation and dispensing of pharmaceuticals.
It takes in-depth knowledge and experience to navigate the intricate regulatory environments of the US and the EU. Our team has extensive experience working with various health agencies like the FDA, EMA, and Health Canada. We understand the importance of building strong relationships with these authorities and can help navigate the complex regulatory environment to achieve your goals.
Here at Zenovel, we provide committed regulatory collaboration services to support the approval and success of your pharmaceutical products in these vital regions.
Experienced professionals with vast knowledge of FDA and EU regulations
Streamline process, Reduce time to market, Minimize delays
Mitigate risk, Enhance approval success rates
Acts as a Local Regulatory Partner for EU & US, Offer insights
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S Certification) is
Lipinski’s Rule of 5 (Ro5) is a crucial guideline in pharmaceutical development, helping researchers evaluate a compound’s likelihood of becoming an effective oral drug. However, with the rapid evolution of therapeutic strategies, it’s worth considering the relevance of Ro5 in the current drug design landscape. Understanding Lipinski’s Rule of 5
Regulatory affairs (RA) play a crucial role in the pharmaceutical industry; ensuring products meet quality, safety, and efficacy. As the industry grow further the need for qualified professionals to bridge gaps between companies and regulators increases. This blog explores Zenovel regulatory affairs expertise, our various facets, and valuable contribution to
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.